Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 16/20 | 0.77 |
| ▸ | MAOB | P27338 | 16/20 | 0.77 |
| ▸ | BRD4 | O60885 | 1/20 | 0.55 |
| ▸ | HPD | P32754 | 1/20 | 0.55 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.52 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL226640 | 0.87 | MAOB (1.00) | MAOAMAOB | |
| SCHEMBL3451690 | 0.84 | MAOB (0.94) | MAOAMAOB | |
| SCHEMBL1028352 | 0.82 | MAOB (0.67) | MAOAMAOBHSD17B1GSTP1 | |
| SCHEMBL21297626 | 0.81 | MAOB (0.88) | MAOAMAOB | |
| SCHEMBL7584101 | 0.80 | HSD17B1 (0.73) | MAOAMAOBHSD17B1 | |
| SCHEMBL30067289 | 0.79 | MAOB (1.00) | MAOAMAOB | |
| SCHEMBL3501723 | 0.79 | MAOB (1.00) | MAOAMAOB | |
| SCHEMBL4085727 | 0.79 | HSD17B1 (0.60) | MAOAMAOBBRD4HSD17B1 | |
| SCHEMBL327001 | 0.79 | MAOB (0.84) | MAOAMAOB | |
| SCHEMBL7218099 | 0.79 | MAOB (0.82) | MAOAMAOBGSTP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| EP-2013176-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | Sterix Limited (GB) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007096647-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | STERIX LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186900-A1 | COMPOUND | HSD17B2, HSD17B11, CYP17A1 | MAOA 470/4885MAOB 494/4885BRD4 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.